

Anders Svenningsson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7498260/anders-svenningsson-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

89
papers

4,421
citations

34
h-index

65
g-index

96
ext. papers

5,355
ext. citations

6.1
avg, IF

5.2
L-index

#	Paper	IF	Citations
89	Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension. <i>Journal of Neurology</i> , 2021 , 268, 651-657	5.5	3
88	Metabolomics of Cerebrospinal Fluid from Healthy Subjects Reveal Metabolites Associated with Ageing. <i>Metabolites</i> , 2021 , 11,	5.6	5
87	Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. <i>JAMA Neurology</i> , 2021 , 78, 1197-1204	17.2	16
86	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , 2020 , 19, 307-316	24.1	77
85	Targeted metabolomics of CSF in healthy individuals and patients with secondary progressive multiple sclerosis using high-resolution mass spectrometry. <i>Metabolomics</i> , 2020 , 16, 26	4.7	7
84	Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. <i>Annals of Neurology</i> , 2020 , 87, 688-699	9.4	43
83	Prevention of post-dural puncture headache: a randomized controlled trial. <i>European Journal of Neurology</i> , 2020 , 27, 871-877	6	6
82	NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102463	4	6
81	Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. <i>JAMA Neurology</i> , 2020 , 77, 184-191	17.2	200
80	Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1532-1539	5	6
79	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. <i>JAMA Neurology</i> , 2019 , 76, 1035-1048	17.2	237
78	Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study. <i>Journal of Neurology</i> , 2019 , 266, 2208-2215	5.5	2
77	Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease. <i>Journal of Neuroimmunology</i> , 2019 , 332, 31-36	3.5	3
76	Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. <i>Acta Neurologica Scandinavica</i> , 2019 , 139, 462-468	3.8	13
75	Inflammatory activity and vitamin D levels in an MS population treated with rituximab. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319826598	2	7
74	Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. <i>European Journal of Neurology</i> , 2019 , 26, 1060-1067	6	19
73	Serum sickness following rituximab therapy in multiple sclerosis. <i>Neurology: Clinical Practice</i> , 2019 , 9, 519-521	1.7	5

72	Reply to Sun et al. <i>Pain</i> , 2019 , 160, 2898-2899	8	
71	Cerebrospinal fluid biomarkers of inflammation in trigeminal neuralgia patients operated with microvascular decompression. <i>Pain</i> , 2019 , 160, 2603-2611	8	14
70	Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. <i>JAMA Neurology</i> , 2018 , 75, 320-327	17.2	101
69	Population-based cohort study on the epidemiology of acute appendicitis in children in Sweden in 1987-2013. <i>BJS Open</i> , 2018 , 2, 142-150	3.9	15
68	Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls. <i>PLoS ONE</i> , 2018 , 13, e0192516	3.7	9
67	Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study. <i>Neurology</i> , 2018 , 91, e1893-e1901	6.5	23
66	Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. <i>Neurology</i> , 2017 , 89, 2230-2237	6.5	205
65	Brain Parenchymal Fraction in Healthy Adults-A Systematic Review of the Literature. <i>PLoS ONE</i> , 2017 , 12, e0170018	3.7	19
64	Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1249-1257	5	13
63	Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society. <i>Acta Neurologica Scandinavica</i> , 2017 , 135, 17-24	3.8	37
62	Vitamin D and axonal injury in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1027-31	5	28
61	Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e271	9.1	82
60	Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. <i>Neurology</i> , 2016 , 87, 141-7	6.5	55
59	Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. <i>Neurology</i> , 2016 , 87, 2074-2081	6.5	187
58	Reply. <i>Annals of Neurology</i> , 2016 , 80, 791-792	9.4	
57	Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e191	9.1	34
56	Rituximab in paediatric onset multiple sclerosis: a case series. <i>Journal of Neurology</i> , 2016 , 263, 322-326	5.5	30
55	Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016 , 292, 40-4	3.5	21

54	How to minimize the risk for headache? A lumbar puncture practice questionnaire study. <i>Ideggyogyaszati Szemle</i> , 2016 , 69, 397-402	0.4	1
53	Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. <i>Annals of Neurology</i> , 2016 , 79, 950-8	9.4	143
52	Brain parenchymal fraction in an age-stratified healthy population determined by MRI using manual segmentation and three automated segmentation methods. <i>Journal of Neuroradiology</i> , 2016 , 43, 384-391	3.1	15
51	Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness. <i>Frontiers in Neurology</i> , 2015 , 6, 18	4.1	27
50	Age-dependent effects on the treatment response of natalizumab in MS patients. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 48-56	5	17
49	Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1036-44	5	50
48	Increasing prevalence of multiple sclerosis in Värderbotten County of Sweden. <i>Acta Neurologica Scandinavica</i> , 2015 , 132, 389-94	3.8	16
47	Improved working ability in a contemporary MS population compared with a historic non-treated MS population in the same geographic area of Sweden. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015 , 1, 2055217315608203	2	1
46	Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction. <i>PLoS ONE</i> , 2015 , 10, e0135886	3.7	71
45	Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015 , 2, e79	9.1	33
44	Lumbar puncture preferences among Swedish neurologists. <i>Neurological Research</i> , 2015 , 37, 92-4	2.7	3
43	Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light. <i>PLoS ONE</i> , 2015 , 10, e0132177	3.7	88
42	Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 1116-21	5.5	108
41	The cerebrospinal fluid cytokine signature of multiple sclerosis: a homogenous response that does not conform to the Th1/Th2/Th17 convention. <i>Journal of Neuroimmunology</i> , 2014 , 277, 153-9	3.5	21
40	Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 43-50	5	81
39	Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1095-101	5	9
38	Fatal neuroinflammation in a case of multiple sclerosis with anti-natalizumab antibodies. <i>Neurology</i> , 2013 , 80, 965-7	6.5	15
37	Automated determination of brain parenchymal fraction in multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2013 , 34, 498-504	4.4	43

36	Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 622-30	5	19
35	Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting. <i>PLoS ONE</i> , 2013 , 8, e58643	3.7	64
34	Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. <i>PLoS ONE</i> , 2013 , 8, e63172	3.7	52
33	Humoral immune response to influenza vaccine in natalizumab-treated MS patients. <i>Neurological Research</i> , 2012 , 34, 730-3	2.7	40
32	Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. <i>Annals of Neurology</i> , 2011 , 69, 83-9	9.4	236
31	Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: productivity gain based on direct measurement of work capacity before and after 1 year of treatment. <i>BioDrugs</i> , 2011 , 25, 299-306	7.9	17
30	A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 708-19	5	80
29	Season of birth and multiple sclerosis in Sweden. <i>Acta Neurologica Scandinavica</i> , 2010 , 121, 20-3	3.8	31
28	Neurofilament light as a prognostic marker in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 287-92	9.2	129
27	Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. <i>Clinical Neuropharmacology</i> , 2010 , 33, 260-4	1.4	55
26	NORDic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , 2009 , 8, 519-29	24.1	85
25	An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. <i>Neurology</i> , 2004 , 62, 2277-82	6.5	229
24	Neurofilament and glial fibrillary acidic protein in multiple sclerosis. <i>Neurology</i> , 2004 , 63, 1586-90	6.5	166
23	Sick leave and professional assistance for multiple sclerosis individuals in Värderbotten County, northern Sweden. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 515-20	5	20
22	Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial. <i>Annals of Neurology</i> , 2002 , 51, 467-74	9.4	22
21	Differential expression of neurotrophic factors and inflammatory cytokines by myelin basic protein-specific and other recruited T cells infiltrating the central nervous system during experimental autoimmune encephalomyelitis. <i>Scandinavian Journal of Immunology</i> , 2002 , 55, 264-73	3.4	45
20	Intra-CNS activation by antigen-specific T lymphocytes in experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2001 , 113, 202-11	3.5	10
19	Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. <i>Journal of Neuroscience</i> , 2000 , 20, 5283-91	6.6	278

18	Nitric oxide metabolites in CSF of patients with MS are related to clinical disease course. <i>Neurology</i> , 1999 , 53, 1880-2	6.5	27
17	Molecular and genetic requirements for preferential recruitment of TCRBV8S2+ T cells in Lewis rat experimental autoimmune encephalomyelitis. <i>Journal of Immunology</i> , 1998 , 160, 681-90	5.3	30
16	Increased expression of B7-1 costimulatory molecule on cerebrospinal fluid cells of patients with multiple sclerosis and infectious central nervous system disease. <i>Journal of Neuroimmunology</i> , 1997 , 75, 59-68	3.5	29
15	Identification and analysis of macrophage-derived foam cells from human atherosclerotic lesions by using a Biotin-FL3 channel in flow cytometry 1997 , 29, 155-164		10
14	Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. <i>Neurology</i> , 1996 , 47, 895-900	6.5	92
13	Lymphocyte phenotype and subset distribution in normal cerebrospinal fluid. <i>Journal of Neuroimmunology</i> , 1995 , 63, 39-46	3.5	92
12	Reduced frequency of memory CD8+ T lymphocytes in cerebrospinal fluid and blood of patients with multiple sclerosis. <i>Autoimmunity</i> , 1995 , 21, 231-9	3	9
11	Differential regulation of macrophage scavenger receptor isoforms: mRNA quantification using the polymerase chain reaction. <i>Journal of Lipid Research</i> , 1995 , 36, 2282-90	6.3	14
10	Human spumaretrovirus antibody reactivity in multiple sclerosis. <i>Journal of Neurology</i> , 1994 , 241, 204-9	5.5	10
9	Cell Adhesion Molecules in Multiple Sclerosis. <i>CNS Drugs</i> , 1994 , 2, 87-95	6.7	1
8	Possible association of HTLV-I infection and dementia. <i>Acta Neurologica Scandinavica</i> , 1993 , 88, 199-203	3.8	6
7	Adhesion molecule expression on cerebrospinal fluid T lymphocytes: evidence for common recruitment mechanisms in multiple sclerosis, aseptic meningitis, and normal controls. <i>Annals of Neurology</i> , 1993 , 34, 155-61	9.4	104
6	HIV-1 in postmortem brain tissue from patients with AIDS: a comparison of different detection techniques. <i>Aids</i> , 1992 , 6, 915-23	3.5	11
5	Simultaneous detection of ferritin and HIV-1 in reactive microglia. <i>Acta Neuropathologica</i> , 1992 , 84, 297-306	3.5	29
4	No evidence for spumavirus or oncovirus infection in relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 1992 , 32, 711-4	9.4	11
3	HIV-1 infection of CD4-negative cells via HTLV pseudovirions. <i>Aids</i> , 1991 , 5, 769	3.5	6
2	HIV-1 propagates in human neuroblastoma cells. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1991 , 4, 228-37		11
1	Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden. <i>Acta Neurologica Scandinavica</i> , 1990 , 82, 161-8	3.8	80

